医学
特发性矮身高
荟萃分析
线性增长
身材矮小
人生长激素
系统回顾
梅德林
儿科
随机对照试验
生长激素治疗
生长激素
内科学
斯科普斯
激素
政治学
法学
数学
应用数学
作者
George Paltoglou,Ioannis Dimitropoulos,Georgia Kourlaba,Evangelia Charmandari
标识
DOI:10.1515/jpem-2020-0287
摘要
Abstract Objectives Idiopathic short stature (ISS) is a recognized, albeit a controversial indication for treatment with recombinant human growth hormone (rhGH). The objective of the present study was to conduct a systematic review of the literature and meta-analyses of selected studies about the use of rhGH in children with ISS on linear growth and adult height (AH). Methods A systematic literature search was conducted to identify relevant studies published till February 28, 2017 in the following databases: Medline (PubMed), Scopus and Cochrane Central Registry of Controlled Trials. After exclusion of duplicate studies, 3,609 studies were initially identified. Of those, 3,497 studies were excluded during the process of assessing the title and/or the abstract. The remaining 112 studies were evaluated further by assessing the full text; 21 of them fulfilled all the criteria in order to be included in the current meta-analysis. Results Children who received rhGH had significantly higher height increment at the end of the first year, an effect that persisted in the second year of treatment and achieved significantly higher AH than the control group. The difference between the two groups was equal to 5.3 cm (95% CI: 3.4–7 cm) for male and 4.7 cm (95% CI: 3.1–6.3 cm) for female patients. Conclusion In children with ISS, treatment with rhGH improves short-term linear growth and increases AH compared with control subjects. However, the final decision should be made on an individual basis, following detailed diagnostic evaluation and careful consideration of both risks and benefits of rhGH administration.
科研通智能强力驱动
Strongly Powered by AbleSci AI